EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Recurrence/prognosis estimation using a molecularly positive surgical margin‐based model calls for alternative curative strategies in pIIIA / N2 NSCLC

Li Li, Kewen He, Tao Zhou, Yang Xu iD, Jiaohui Pang, Qingxi Yu, Yongsheng Gao, Hongjin Shi, He Zhu, Mengke Li, Jinming Yu iD, Shuanghu Yuan iD

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Li Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Natural Science Innovation and Development Joint Foundation of Shandong, Foundation of Natural Science Foundation of Shandong.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stage pIIIA/N2 non‐small cell lung cancer (NSCLC) is primarily treated by complete surgical resection combined with neoadjuvant/adjuvant therapies. However, up to 40% of patients experience tumor recurrence. Here, we studied 119 stage pIIIA/N2 NSCLC patients who received complete surgery plus adjuvant chemotherapy (CT) or chemoradiotherapy (CRT). The paired tumor and resection margin samples were analyzed using next‐generation sequencing (NGS). Although all patients were classified as negative resection margins by histologic methods, NGS revealed that 47.1% of them had molecularly positive surgical margins. Patients who tested positive for NGS‐detected residual tumors had significantly shorter disease‐free survival (DFS) ( P = 0.002). Additionally, metastatic lymph node ratio, erb‐b2 receptor tyrosine kinase 2 ( ERBB2 ) mutations, and SWI/SNF‐related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily a, member 4 ( SMARCA4 ) mutations were also independently associated with DFS. We used these four features to construct a COX model that could effectively estimate recurrence risk and prognosis. Notably, mutational profiling through broad‐panel NGS could more sensitively detect residual tumors than the conventional histologic methods. Adjuvant CT and adjuvant CRT exhibited no significant difference in eliminating locoregional recurrence risk for stage pIIIA/N2 NSCLC patients with molecularly positive surgical margins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasm Recurrence, LocalHumansFemaleMiddle AgedMalePrognosisAgedMargins of ExcisionDisease-Free SurvivalNeoplasm StagingMutationAdultHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

COX modelmetastatic lymph node ratiomolecularly positive surgical marginnext‐generation sequencingnon‐small cell lung cancer

Autor:innen und Institutionen

  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.
  • Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, C…
  • Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, China.
  • Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

ORCID-Profile: Yang Xu, Jinming Yu, Shuanghu Yuan

Förderung

  • Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences
  • Natural Science Innovation and Development Joint Foundation of Shandong
  • Foundation of Natural Science Foundation of Shandong
  • Academic Promotion Program of Shandong First Medical University
  • Taishan Scholars Program
  • Natural Science Youth Foundation of Shandong
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Li, L., He, K., Zhou, T., Xu, Y., Pang, J., Yu, Q., Gao, Y., Shi, H., Zhu, H., Li, M., Yu, J., & Yuan, S. (2024). Recurrence/prognosis estimation using a molecularly positive surgical margin‐based model calls for alternative curative strategies in pIIIA / N2 NSCLC. Molecular Oncology. https://doi.org/10.1002/1878-0261.13600

Vancouver

Li L, He K, Zhou T, Xu Y, Pang J, Yu Q, et al. Recurrence/prognosis estimation using a molecularly positive surgical margin‐based model calls for alternative curative strategies in pIIIA / N2 NSCLC. Molecular Oncology. 2024. doi:10.1002/1878-0261.13600

BibTeX
@article{Li2024,
  author = {Li, Li and He, Kewen and Zhou, Tao and Xu, Yang and Pang, Jiaohui and Yu, Qingxi and Gao, Yongsheng and Shi, Hongjin and Zhu, He and Li, Mengke and Yu, Jinming and Yuan, Shuanghu},
  title = {Recurrence/prognosis estimation using a molecularly positive surgical margin‐based model calls for alternative curative strategies in pIIIA / N2 NSCLC},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13600}
}
Kostenlos starten →